ValuEngine downgraded shares of Bellus Health (OTCMKTS:BLUSF) from a hold rating to a sell rating in a research report released on Friday morning.
Bellus Health (BLUSF) opened at $0.33 on Friday. Bellus Health has a 1-year low of $0.18 and a 1-year high of $0.36.
COPYRIGHT VIOLATION NOTICE: This report was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.com-unik.info/2017/12/05/bellus-health-blusf-stock-rating-lowered-by-valuengine.html.
BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company’s pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Bellus Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bellus Health Inc. and related companies.